Nimotop S (Nimodipine)

Nimodipine, the active ingredient in Nimotop S, is a calcium channel blocker presented as an injectable for intravenous use. It is employed to prevent cerebral vasospasm after subarachnoid hemorrhage and to provide neuroprotection following acute brain injury. GNH USA supplies Nimotop S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimodipine, marketed as Nimotop S, works on cerebral vessels to prevent vasospasm and protect neural tissue after acute events. - Prevention of cerebral vasospasm following subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits by maintaining arterial diameter. - Neuroprotection after acute brain injury: improves cerebral blood flow and oxygen delivery, helping limit neuronal damage. - Management of cerebral ischemia in neurosurgical patients: supports adequate perfusion during postoperative recovery.

Adverse reactions may occur with intravenous nimodipine and should be monitored.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Flushing or warmth sensation: cutaneous vasodilation. - Dizziness or light‑headedness: related to blood pressure changes. - Tachycardia: compensatory increase in heart rate.

Serious or Rare Side Effects: - Severe hypotension leading to syncope or organ hypoperfusion. - Myocardial ischemia or infarction in susceptible patients. - Life‑threatening arrhythmias such as ventricular tachycardia. - Hepatic dysfunction with elevated transaminases. - Anaphylactic or severe allergic reactions. - Seizures or worsening neurological status.

Use of Nimotop S requires careful clinical assessment and monitoring. - Blood pressure monitoring: check systolic and diastolic values before and during infusion. - Hepatic impairment: dose adjustment or heightened observation may be needed. - Concomitant vasodilators: avoid additive hypotensive effects. - Severe hypotension: contraindicated in patients with already low blood pressure. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Nimodipine can interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma levels. - Other calcium‑channel blockers: additive vasodilatory effect can cause profound hypotension. - Nitrates or nitric‑oxide donors: risk of severe blood pressure fall.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic concentration. - Beta‑blockers: combined effect on heart rate and blood pressure requires observation. - Diuretics: may enhance hypotensive response, necessitating dose titration.